Clinical trials: Cancer of Kidney
Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC)
Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT
The goal of this clinical trial is to evaluate whether Finerenone and Empagliflozin, either alone or in combination, can delay the progression of renal function decline in patients at high risk for chronic kidney disease (CKD)…
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Nephrectomy, Chronic Kidney Disease(CKD)
- Trial name
- EmFin-Nx (NCT06818305)
- Testing
- Finerenone (BAY 94-8862), Empagliflozin 10 mg
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jinling Hospital, China
Kidney Cancer
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
The goal of this clinical research study is to compare the effectiveness of Afinitor (everolimus) and Sutent (sunitinib) for the treatment of advanced renal cell carcinoma (kidney cancer).
- Trial name
- NCT01185366
- Testing
- Everolimus, Sunitinib
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
The Effect of Different Doses of Remifentanil on Kidney Function During Robot Assisted Prostatectomy - A Retrospective Study
Robot assisted prostatectomy reduces the patients' postoperative pain and leads to rapid rehabilitation. But pneumoperitoneum affects the kidney.
- Trial name
- NCT02041559
- Where
- South Korea
- Volunteers
- 1,500 people
- Sponsor
- Yonsei University
Metastatic Melanoma, Renal Cell Cancer
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
Background: -Although IL-2 can shrink tumors in about 20 percent of patients with metastatic kidney cancer and in 15 percent of patients with metastatic melanoma, it is not fully known how the drug works.
- Trial name
- NCT00304460
- Testing
- aldesleukin
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumours
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
To determine the effect of renal impairment and prior platinum-based chemotherapy on the safety and blood levels of topotecan administered orally
- Trial name
- NCT00483860
- Testing
- Topotecan
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Adenocarcinoma of Prostate, Radical Prostatectomy
Multimodal Machine Learning Characterization of Solid Tumors
This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness.
- Conditions
- Adenocarcinoma of Prostate, Radical Prostatectomy, Hepatocellular Carcinoma (HCC), Glioma
- Trial name
- NCT04687969
- Testing
- [18F]DCFPyL, PET/MRI scanner
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ciprian Catana, MD, PhD
Advanced Renal Cell Carcinoma
Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma
This is a study to evaluate the safety, efficacy and pharmacokinetics of temsirolimus in Asian patients with advanced renal cell carcinoma. The trial is only being conducted in Japan, Korea, and China.
- Trial name
- NCT00494091
- Testing
- Temsirolimus (CCI-779)
- Where
- 24 sites in China, Japan and 1 more
- Volunteers
- 82 people
- Sponsor
- Pfizer
Renal Cell Carcinoma Metastatic, Renal Cell Carcinoma
Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC
This is a retrospective cohort study aiming to collect data on patients' characteristics, resource utilization, adverse events management and calculate costs attributed to current treatments of advance RCC patients who have…
- Trial name
- NCT03699579
- Where
- 2 sites in Taiwan
- Volunteers
- 28 people
- Sponsor
- Ipsen
Kidney Cancer
Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00003683
- Testing
- doxorubicin hydrochloride, ifosfamide
- Where
- 14 sites in France
- Volunteers
- 40 people
- Sponsor
- UNICANCER
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Kidney Neoplasms
MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers
The knowledge of the histological diagnosis and its subtype of a renal parenchymal tumor is important for determine whether the choice of a specific regimen of chemotherapy, target therapy and immunotherapy could be suitable and…
- Trial name
- NCT06126159
- Testing
- multiparametric and fat-detection magnetic resonance imaging (MRI)
- Where
- Taiwan
- Volunteers
- 44 people
- Sponsor
- Chang Gung Memorial Hospital
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
68Ga- and 18F-CAIX PET Imaging Study
This exploratory clinical imaging study will evaluate the safety, tolerability, biodistribution, lesion detection, and tumor uptake characteristics of 68Ga- and 18F-labeled carbonic anhydrase IX (CAIX)-targeted positron emission…
- Conditions
- Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Renal Tumor
- Trial name
- CAIX-PET (NCT07875946)
- Testing
- 68Ga-CAIX PET/CT, 18F-CAIX
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
This is a Phase II Clinical Trial that will evaluate the use of adaptive dosing of pembro-axi in patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
- Trial name
- NCT06860386
- Testing
- Pembrolizumab, Axitinib
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced Renal Cell Carcinoma, Advanced Mesothelioma
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
To find a recommended dose of donated NK cells that can be given with lymphodepleting chemotherapy to patients with advanced renal cell carcinoma, mesothelioma, or osteosarcoma. The effects of this therapy will also be studied.
- Conditions
- Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma
- Trial name
- NCT05703854
- Testing
- CAR.70/IL15-transduced CB-derived NK cells, Fludarabine phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Carcinoma, Kidney Neoplasm
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
This was a Phase 1, open-label, dose-escalation study of yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250) in patients with advanced, measurable clear cell renal cell carcinoma (RCC).
- Conditions
- Renal Cell Carcinoma, Kidney Neoplasm, Renal Cancer, Kidney Cancer
- Trial name
- NCT00199875
- Testing
- Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Ludwig Institute for Cancer Research
Genito Urinary Cancer, Bladder Cancer
Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers
The objective of this study is to obtain human blood CD34+ hematopoietic stem/progenitor cells (HSPCs) to reconstitute a match human immune system in our PDX model.
- Conditions
- Genito Urinary Cancer, Bladder Cancer, Kidney Cancer, Prostate Cancer
- Trial name
- Immune PDX (NCT03134027)
- Testing
- Bone marrow biopsy, Tumor biopsy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Prostate Cancer, Kidney Cancer
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
The goal of this clinical trial is to test the utility of patient navigation by comparing high intensity patient navigation to low intensity navigation approaches to improving cancer trial enrollment of patients treated in…
- Trial name
- NCT06138067
- Testing
- High intensity approach, Low intensity approach
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Renal Cell Carcinoma
A Phase II Study of AS1411 in Renal Cell Carcinoma
The aim of this study is to evaluate the efficacy of AS1411 in patients with Metastatic Renal Cell Carcinoma
- Trial name
- NCT00740441
- Testing
- AS1411
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Antisoma Research
Carcinoma, Renal Cell
Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)
A multicenter uncontrolled study of sorafenib in patients with unresectable and/or metastatic renal cell carcinoma (RCC) to assess the pharmacokinetic profile, safety and tolerability, and efficacy.
- Trial name
- NCT00586105
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 8 sites in China, Taiwan
- Volunteers
- 39 people
- Sponsor
- Bayer